Bruker BioSciences Corporation to Release Third Quarter Financial Results on November 2, 2005

Bruker BioSciences Corporation (NASDAQ:BRKR) plans to
release its third quarter 2005 financial results on Wednesday,
November 2, 2005 after the market closes. Bruker BioSciences will then
host an operator-assisted earnings conference call at 5 p.m. EST. To
listen to the webcast, investors can go to www.bruker-biosciences.com
and click on the live web broadcast symbol. The webcast will be
available through the Company web site for 30 days.
   Investors can also listen and participate on the telephone in the
US and Canada by calling 888-339-2688, or 617-847-3007 outside the US
and Canada. Investors should refer to the Bruker BioSciences Quarterly
Earnings Call. A telephone replay of the conference call will be
available two hours after the conference call by dialing 888-286-8010
in the US and Canada, or 617-801-6888 outside the US and Canada, and
then entering replay pass code 39147513.

   ABOUT BRUKER BIOSCIENCES

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker AXS
Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and
provider of life science and advanced materials research tools based
on X-ray technology. Bruker Daltonics is a leading developer and
provider of innovative life science tools based on mass spectrometry.
Bruker Daltonics also offers a broad line of nuclear, biological and
chemical (NBC) detection products for defense and homeland security.
For more information, please visit www.bruker-biosciences.com

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-K for the year ended December 31,
2004, our most recent quarterly reports on Form 10-Q, and our current
reports on Form 8-K. We disclaim any intent or obligation to update
these forward-looking statements.